S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Billionaires Are Now FLOODING Into Gold (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Billionaires Are Now FLOODING Into Gold (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Billionaires Are Now FLOODING Into Gold (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Billionaires Are Now FLOODING Into Gold (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Billionaires Are Now FLOODING Into Gold (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Billionaires Are Now FLOODING Into Gold (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Billionaires Are Now FLOODING Into Gold (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Billionaires Are Now FLOODING Into Gold (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
NASDAQ:KURA

Kura Oncology (KURA) Stock Price, News & Analysis

$20.25
+0.66 (+3.37%)
(As of 02/23/2024 ET)
Today's Range
$19.58
$20.69
50-Day Range
$12.35
$21.13
52-Week Range
$7.41
$22.92
Volume
572,569 shs
Average Volume
1.50 million shs
Market Capitalization
$1.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.28

Kura Oncology MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
39.6% Upside
$28.28 Price Target
Short Interest
Bearish
14.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.76
Upright™ Environmental Score
News Sentiment
0.40mentions of Kura Oncology in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$1.95 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.09) to ($2.29) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.44 out of 5 stars

Medical Sector

305th out of 943 stocks

Pharmaceutical Preparations Industry

131st out of 430 stocks


KURA stock logo

About Kura Oncology Stock (NASDAQ:KURA)

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

KURA Stock Price History

KURA Stock News Headlines

AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
KURA Mar 2024 25.000 call
KURA Mar 2024 22.500 put
Kura Oncology (NASDAQ:KURA) Cut to Sell at StockNews.com
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
KURA Mar 2024 30.000 call
Kura Oncology: Ziftomenib's Path To AML Market Widens
Kura Shares Rally After Promising Phase 1 Trial Data
See More Headlines
Receive KURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
2/24/2024
Next Earnings (Confirmed)
2/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KURA
Fax
N/A
Employees
131
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$28.28
High Stock Price Target
$37.00
Low Stock Price Target
$10.50
Potential Upside/Downside
+39.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-135,840,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.28 per share

Miscellaneous

Free Float
72,026,000
Market Cap
$1.54 billion
Optionable
Optionable
Beta
0.85
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Troy Edward Wilson J.D. (Age 55)
    Ph.D., Chairman, CEO & President
    Comp: $1.06M
  • Ms. Kathleen Ford (Age 77)
    Chief Operating Officer
    Comp: $754.24k
  • Dr. Stephen Dale M.D. (Age 52)
    Chief Medical Officer
    Comp: $684.41k
  • Mr. Thomas Doyle (Age 53)
    Senior VP of Finance & Accounting
  • Mr. Pete De Spain
    Executive Vice President of Investor Relations & Corporate Communications
  • Ms. Teresa Brophy Bair Esq. (Age 53)
    J.D., Chief Legal Officer & Corporate Secretary
  • Dr. Roger Bakale Ph.D.
    Senior Vice President of Manufacturing & Supply Chain
  • Ms. Maureen Clancy M.B.A.
    VP and Global Head of Program Leadership & Project Management
  • Dr. Mollie Leoni M.D.
    Executive Vice President of Clinical Development
  • Mr. Brian T. Powl M.B.A. (Age 50)
    M.S., Chief Commercial Officer














KURA Stock Analysis - Frequently Asked Questions

Should I buy or sell Kura Oncology stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" KURA shares.
View KURA analyst ratings
or view top-rated stocks.

What is Kura Oncology's stock price target for 2024?

8 Wall Street research analysts have issued twelve-month price targets for Kura Oncology's shares. Their KURA share price targets range from $10.50 to $37.00. On average, they anticipate the company's stock price to reach $28.28 in the next year. This suggests a possible upside of 39.6% from the stock's current price.
View analysts price targets for KURA
or view top-rated stocks among Wall Street analysts.

How have KURA shares performed in 2024?

Kura Oncology's stock was trading at $14.38 on January 1st, 2024. Since then, KURA stock has increased by 40.8% and is now trading at $20.25.
View the best growth stocks for 2024 here
.

When is Kura Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our KURA earnings forecast
.

How can I listen to Kura Oncology's earnings call?

Kura Oncology will be holding an earnings conference call on Tuesday, February 27th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) released its earnings results on Thursday, November, 4th. The company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.04. During the same period in the prior year, the business posted ($0.42) EPS.

What ETF holds Kura Oncology's stock ?

Simplify Propel Opportunities ETF holds 80,000 shares of KURA stock, representing 0.79% of its portfolio.

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by many different institutional and retail investors. Top institutional investors include BVF Inc. IL (9.68%), Vanguard Group Inc. (5.30%), Armistice Capital LLC (2.99%), Dimensional Fund Advisors LP (2.70%), Franklin Resources Inc. (1.82%) and Commodore Capital LP (1.64%). Insiders that own company stock include Kathleen Ford, Kirsten Flowers, Teresa Brophy Bair, Thomas James Doyle, Thomas Malley and Troy Edward Wilson.
View institutional ownership trends
.

How do I buy shares of Kura Oncology?

Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KURA) was last updated on 2/24/2024 by MarketBeat.com Staff